Houston Methodist West Hospital

Medicine & Life Sciences

1. Radiotherapy 100%
2. Survival 87%
3. Breast Neoplasms 50%
4. Databases 49%
5. Mammaplasty 48%
6. Radiosurgery 46%
7. Breast 43%
8. Neoplasms 40%
9. Therapeutics 39%
10. Chemoradiotherapy 35%
11. Drug Therapy 33%
12. Prostatic Hyperplasia 30%
13. Ventricular Tachycardia 29%
14. Renal Cell Carcinoma 29%
15. Mortality 29%
16. Non-Small Cell Lung Carcinoma 28%
17. Prostatitis 24%
18. Surgeons 23%
19. Esophageal Neoplasms 23%
20. Segmental Mastectomy 23%
21. Herniorrhaphy 23%
22. Endotoxemia 23%
23. Acellular Dermis 23%
24. Mastectomy 22%
25. Safety 21%
26. Ventral Hernia 21%
27. Recurrence 20%
28. Catheter Ablation 20%
29. Plastic Surgery 19%
30. Elderly 19%
31. Free Tissue Flaps 18%
32. Platelet-Rich Plasma 18%
33. Cystectomy 17%
34. Erectile Dysfunction 17%
35. Doxazosin 16%
36. Penile Prosthesis 16%
37. Wounds and Injuries 16%
38. Urinary Bladder Neoplasms 15%
39. Nephrectomy 15%
40. Systematic Reviews 15%
41. Adenocarcinoma 14%
42. Thorax 14%
43. Comorbidity 14%
44. Endotoxins 14%
45. Population 14%
46. Lupus Nephritis 13%
47. Propensity Score 13%
48. Glioblastoma 13%
49. Neoplasm Metastasis 13%
50. Dissecting Aneurysm 13%
51. Terminal Care 13%
52. Kidney 13%
53. Prostate 13%
54. Return to Sport 13%
55. Logistic Models 13%
56. Quality Improvement 13%
57. Small Cell Lung Carcinoma 12%
58. Intensive Care Units 12%
59. Morbidity 12%
60. Mentors 11%
61. Placebos 11%
62. Brachytherapy 11%
63. Incidence 11%
64. Hand 11%
65. Kaplan-Meier Estimate 11%
66. Statistics 11%
67. Lymph Nodes 11%
68. Wrist 10%
69. Adjuvant Radiotherapy 10%
70. Finasteride 10%
71. Guidelines 10%
72. Glioma 10%
73. Uterine Cervical Neoplasms 10%
74. Cicatrix 10%
75. Patient Selection 10%
76. Adjuvant Chemotherapy 10%
77. Lobular Carcinoma 10%
78. Melanoma 10%
79. Triple Negative Breast Neoplasms 10%
80. Negative-Pressure Wound Therapy 10%
81. Perforator Flap 10%
82. Lipectomy 10%
83. Brain 10%
84. Confidence Intervals 10%
85. Reoperation 9%
86. Nephrolithiasis 9%
87. Muscles 9%
88. Tumor Necrosis Factor Receptors 9%
89. Ventilator-Associated Pneumonia 9%
90. Immunotherapy 9%
91. Length of Stay 9%
92. Infections 9%
93. Esthetics 9%
94. Prostatic Neoplasms 9%
95. Rituximab 9%
96. Carcinoma 9%
97. Kidney Calculi 9%
98. Veins 9%
99. Antiphospholipid Syndrome 9%
100. Tissue Donors 9%